GDUFA II Reviews Start Strong With High First-Cycle Approval Rate
Executive Summary
Performance numbers are likely to fluctuate over the course of the program, but the rate of first-cycle approvals during the first month of the new user fee program is more than double the rate during the last year of the old iteration.
You may also be interested in...
Lack Of Priority? No ANDAs Approved Using Expedited Pathway In FY 2018
US FDA also refused to receive many priority generic drug applications, suggesting the expedited pathway may not be working as intended quite yet.
Lack Of Priority? No ANDAs Approved Using Expedited Pathway In FY 2018
US FDA also refused to receive many priority generic drug applications, suggesting the expedited pathway may not be working as intended quite yet.
US FDA's Generics Program Reaches 'Steady State' Milestone
OGD Director Uhl says program is now in balance between the number of submissions and agency review actions.